Cannabis and Clinical Trials: How the First Cannabis Extract Got FDA Approval
In June, Colorado State University-Pueblo hosted Clayton Snell, a pharmacist at Greenwich Biosciences, to discuss the company’s work on epilepsy and developing cannabis plant-derived products to be...
View ArticleFDA Rejects Two Applications for CBD-based Dietary Supplements
The cannabidiol industry hit a hurdle on Wednesday with the Food and Drug Administration rejection of two “new dietary ingredient” (NDI) applications for full-spectrum hemp extract that contained...
View ArticleFDA Launches Biggest Cannabis Data Collection Plan Yet
The Food and Drug Administration is ramping up its collection of data on cannabis-derived products. To that end, late last week, the FDA quietly released the “Cannabis-Derived Products Data...
View ArticleFDA: The Cannabis Regulatory Landscape is “Complex”
The path for federally-regulated cannabidiol isn’t getting any clearer. Cannabis regulation was in the spotlight during a Food and Drug Law Institute symposium last week. The online event focused on...
View ArticleFDA Reiterates Need for Cannabinoid Data in Webinar on Research and Regulation
Much of the information coming out of the U.S. Food and Drug Administration about CBD in recent months and years has been, basically: we need more info. The FDA is charged with creating the...
View ArticleFDA Issues More CBD Warning Letters, With a Focus on Covid Claims
The U.S. Food and Drug Administration is again taking aim at companies peddling cannabidiol (CBD) products that contain far-reaching health claims on their labels. The 2018 Farm Bill legalized...
View ArticleFDA Announces Plan to Work with Congress on “New” Path for CBD Products
The Food and Drug Administration said on Thursday that it will work with Congress to figure out how to regulate the CBD industry, marking one of the agency’s most significant cannabis-related...
View ArticleAs the FDA Turns to Congress for CBD Regs, Here’s Who’s Been Lobbying on CBD
The U.S. Food and Drug Administration made waves last month when it announced that it would not be crafting rules to guide the cannabidiol (CBD) industry after all. Instead, it is “prepared to work...
View ArticleFDA’s Cannabis Advisor: Approach to CBD Rules Shouldn’t Let “Perfect be the...
So far in 2023, the U.S. Food and Drug Administration, not Congress, has made the biggest waves in the cannabis industry. The FDA announced in late January that it would work with Congress to figure...
View ArticleCongress Picks Up the Baton from the FDA on CBD, Seeking Data
Members of Congress issued a bicameral Request for Information this week, asking for a wide range of data from “subject matter experts and stakeholders regarding Food and Drug Administration (FDA)...
View Article